EA200100959A1 - PHARMACEUTICAL COMPOSITION IN STANDARD FORM, CONTAINING ACETYLSALICYLIC ACID AND CLINIC HEAT SULFATE - Google Patents

PHARMACEUTICAL COMPOSITION IN STANDARD FORM, CONTAINING ACETYLSALICYLIC ACID AND CLINIC HEAT SULFATE

Info

Publication number
EA200100959A1
EA200100959A1 EA200100959A EA200100959A EA200100959A1 EA 200100959 A1 EA200100959 A1 EA 200100959A1 EA 200100959 A EA200100959 A EA 200100959A EA 200100959 A EA200100959 A EA 200100959A EA 200100959 A1 EA200100959 A1 EA 200100959A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical composition
acetylsalicylic acid
sulfate
clinic
heat
Prior art date
Application number
EA200100959A
Other languages
Russian (ru)
Inventor
Бернар Абрамовиси
Жан Леритьер
Original Assignee
Санофи-Синтелябо
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Санофи-Синтелябо filed Critical Санофи-Синтелябо
Publication of EA200100959A1 publication Critical patent/EA200100959A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Surgery (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Данное изобретение относится к фармацевтической композиции, содержащей в стандартной галеновой форме комбинацию активных начал, обладающих антиагрегационной активностью в отношении тромбоцитов, состоящую из ацетилсалициловой кислоты и гидросульфата клопидогрела.Международная заявка была опубликована вместе с отчетом о международном поиске.This invention relates to a pharmaceutical composition comprising, in a standard galenical form, a combination of active principles with anti-aggregation activity against platelets, consisting of acetylsalicylic acid and clopidogrel hydrogen sulfate. The international application was published together with an international search report.

EA200100959A 1999-04-30 2000-04-25 PHARMACEUTICAL COMPOSITION IN STANDARD FORM, CONTAINING ACETYLSALICYLIC ACID AND CLINIC HEAT SULFATE EA200100959A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9905497A FR2792836B3 (en) 1999-04-30 1999-04-30 PHARMACEUTICAL COMPOSITION IN UNIT FORM CONTAINING ASPIRIN AND CLOPIDOGREL HYDROGENOSULFATE
PCT/FR2000/001086 WO2000066130A1 (en) 1999-04-30 2000-04-25 Pharmaceutical composition in unit form containing acetylsalcylic acid and clopidogrel hydrogenosulphate

Publications (1)

Publication Number Publication Date
EA200100959A1 true EA200100959A1 (en) 2002-06-27

Family

ID=9545071

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200100959A EA200100959A1 (en) 1999-04-30 2000-04-25 PHARMACEUTICAL COMPOSITION IN STANDARD FORM, CONTAINING ACETYLSALICYLIC ACID AND CLINIC HEAT SULFATE

Country Status (24)

Country Link
EP (1) EP1178809A1 (en)
JP (1) JP2002543137A (en)
KR (1) KR20020005735A (en)
CN (1) CN1359294A (en)
AR (1) AR023789A1 (en)
AU (1) AU4303600A (en)
BR (1) BR0010194A (en)
CA (1) CA2371231A1 (en)
CZ (1) CZ20013887A3 (en)
EA (1) EA200100959A1 (en)
EE (1) EE200100559A (en)
FR (1) FR2792836B3 (en)
HK (1) HK1041823A1 (en)
HU (1) HUP0202329A2 (en)
IL (1) IL145648A0 (en)
IS (1) IS6084A (en)
MX (1) MXPA01011071A (en)
NO (1) NO20015295L (en)
NZ (1) NZ514248A (en)
PL (1) PL351923A1 (en)
SK (1) SK15542001A3 (en)
TR (1) TR200103039T2 (en)
UY (1) UY26131A1 (en)
WO (1) WO2000066130A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0400644A3 (en) 2000-12-25 2009-06-29 Ube Industries Pharmaceutical compositions containing aspirin
US6767913B2 (en) 2001-12-18 2004-07-27 Teva Pharmaceutical Industries Ltd. Crystal forms iii, iv, v, and novel amorphous form of clopidogrel hydrogensulfate, processes for their preparation, processes for the preparation of form i, compositions containing the new forms and methods of administering the new forms
US7074928B2 (en) 2002-01-11 2006-07-11 Teva Pharmaceutical Industries, Ltd. Polymorphs of clopidogrel hydrogensulfate
IL166593A0 (en) 2002-08-02 2006-01-15 Racemization and enantiomer separation of clopidogrel
US6800759B2 (en) 2002-08-02 2004-10-05 Teva Pharmaceutical Industries Ltd. Racemization and enantiomer separation of clopidogrel
JP4917255B2 (en) * 2003-10-16 2012-04-18 第一三共ヘルスケア株式会社 Oral composition containing salicylic acids
WO2005070464A2 (en) * 2004-01-21 2005-08-04 Biofarma Ilac Sanayi Ve Ticaret A.S. A tablet formulation of clopidogrel bisulphate
BRPI0611626A2 (en) * 2005-06-13 2010-09-21 Elan Pharma Int Ltd Combination Formulations of Clopidogrel and Aspirin Nanoparticles
KR20070009851A (en) * 2005-07-14 2007-01-19 씨제이 주식회사 Pharmaceutical compositions containing clopidogrel bisulfate
EP1926736A4 (en) * 2005-09-21 2010-08-25 Chong Kun Dang Pharm Corp Novel resinate complex of s-clopidogrel and production method thereof
KR20070044323A (en) * 2005-10-24 2007-04-27 에스케이케미칼주식회사 Stabilized pharmaceutical oral preparation containing clopidogrel bisulfate
US20100145053A1 (en) * 2006-04-05 2010-06-10 Cadila Healthcare Limited Modified release clopidogrel formulation
EP1900358A1 (en) * 2006-09-16 2008-03-19 Cimex Pharma AG Pharmaceutical formulations comprising clopidogrel
HUP0600839A3 (en) * 2006-11-14 2008-09-29 Egis Gyogyszergyar Nyrt Solid pharmaceutical composition containing polymorph i of clopidogrel hydrogensulfate and process for the preparation thereof
JP2011512406A (en) * 2008-02-22 2011-04-21 ハナル バイオファーマ カンパニー リミテッド Compound preparation
CN101695496A (en) * 2009-10-15 2010-04-21 苏春华 Medicinal composition containing triflusal and clopidogrel
JP2013032289A (en) * 2009-10-28 2013-02-14 Daiichi Sankyo Co Ltd Wax stable formulation
RU2484820C2 (en) * 2011-02-24 2013-06-20 Общество с ограниченной ответственностью "Озон" Combined medicine as thrombocyte aggregation inhibitor
KR101675501B1 (en) * 2011-11-02 2016-11-14 한국유나이티드제약 주식회사 Combination of Clopidogrel and Aspirin
CN102406938A (en) * 2011-11-29 2012-04-11 北京阜康仁生物制药科技有限公司 Medicine composition for resisting thrombosis
JP6004524B2 (en) * 2012-07-11 2016-10-12 大原薬品工業株式会社 Method for producing clopidogrel sulfate-containing tablets
WO2015015062A1 (en) * 2013-08-02 2015-02-05 Sanofi Pharmaceutical tablet comprising acetylsalicylic acid and clopidogrel
CN104434932B (en) * 2014-12-18 2017-05-24 成都苑东生物制药股份有限公司 Pharmaceutical composition of clopidogrel hydrogen sulfate and acetylsalicylic acid tablet and preparation method thereof
WO2017037741A1 (en) * 2015-09-02 2017-03-09 Sun Pharmaceutical Industries Ltd Compact solid dosage form of aspirin and clopidogrel
CN115737578A (en) * 2022-11-23 2023-03-07 石家庄四药有限公司 Clopidogrel hydrogen sulfate and aspirin compound tablet and preparation method thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2623810B2 (en) 1987-02-17 1992-01-24 Sanofi Sa ALPHA SALTS- (TETRAHYDRO-4,5,6,7 THIENO (3,2-C) PYRIDYL-5) (2-CHLORO-PHENYL) -THETHYL ACETATE DEXTROGYRE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
US5576328A (en) * 1994-01-31 1996-11-19 Elf Sanofi Method for the secondary prevention of ischemic events
FR2744918B1 (en) 1996-02-19 1998-05-07 Sanofi Sa NEW COMBINATIONS OF ACTIVE INGREDIENTS CONTAINING THIENO (3,2-C) PYRIDINE DERIVATIVE AND AN ANTITHROMBOTIC
FR2779726B1 (en) 1998-06-15 2001-05-18 Sanofi Sa POLYMORPHIC FORM OF CLOPIDOGREL HYDROGENOSULFATE

Also Published As

Publication number Publication date
FR2792836B3 (en) 2001-07-27
NZ514248A (en) 2003-06-30
PL351923A1 (en) 2003-06-30
FR2792836A1 (en) 2000-11-03
MXPA01011071A (en) 2002-07-22
BR0010194A (en) 2002-02-13
JP2002543137A (en) 2002-12-17
TR200103039T2 (en) 2002-01-21
KR20020005735A (en) 2002-01-17
HK1041823A1 (en) 2002-07-26
EE200100559A (en) 2003-02-17
IL145648A0 (en) 2002-06-30
WO2000066130A1 (en) 2000-11-09
NO20015295D0 (en) 2001-10-29
IS6084A (en) 2001-09-25
SK15542001A3 (en) 2002-02-05
CZ20013887A3 (en) 2002-02-13
CN1359294A (en) 2002-07-17
AR023789A1 (en) 2002-09-04
UY26131A1 (en) 2000-12-29
CA2371231A1 (en) 2000-11-09
EP1178809A1 (en) 2002-02-13
NO20015295L (en) 2001-12-21
AU4303600A (en) 2000-11-17
HUP0202329A2 (en) 2002-10-28

Similar Documents

Publication Publication Date Title
EA200100959A1 (en) PHARMACEUTICAL COMPOSITION IN STANDARD FORM, CONTAINING ACETYLSALICYLIC ACID AND CLINIC HEAT SULFATE
ES2037866T3 (en) A DEODORATING COMPOSITION IN THE FORM OF GEL.
EA200000920A1 (en) DERIVATIVES OF BICYCLIC HYDROXAMIC ACIDS
EA199900532A1 (en) NITROGEN OXIDE SYNTHASE INHIBITORS
ES2176684T3 (en) NEW ASSOCIATIONS OF ACTIVE PRINCIPLES CONTAINING CLOPIDOGREL AND AN ANTHROMBOTIC.
ATE172359T1 (en) COLD STERILIZER WITH EXTENDED ACTIVITY
DE69925133D1 (en) PYRROLOBENZODIAZEPINE
SE0302923D0 (en) Boswellin compositions enhanced with 3-beta-acetyl-11-keto-beta-boswellic acid (AKBA), industrial manufacture and their uses
DK1578406T3 (en) Modified Release Pharmaceutical Composition
ATE359823T1 (en) COMPOSITION CONTAINING AN ANTIFOLATE AND A METHYLMALONIC ACID LOWERING AGENT
ATE239709T1 (en) RACEMIC HUPERZINE A
IS6654A (en) Stable gabapentin with pH within the controlled range
EA200100540A1 (en) PHARMACEUTICAL COMPOSITION WITH MODIFIED SURVIVAL OF THE SENSITIZER TO INSULIN
EA200702496A1 (en) LOCAL COMPOSITION CONTAINING GELATIN
BR0307696A (en) Deodorant or antiperspirant composition
BR0314787A (en) Modified Release Dosage Form
SE9803272D0 (en) A drug for cell regeneration
BR9802803A (en) action and pharmaceutical compositions containing them.
EA200100802A1 (en) APPLICATION OF TIANEPTIN IN THE PREPARATION OF MEDICINES INTENDED FOR THE TREATMENT OF NEURODEGENERATIVE PATHOLOGIES
EA200400751A1 (en) APPLICATION OF DEOXYPEGANINE FOR THE TREATMENT OF CLINICAL DEPRESSION
DE60302951D1 (en) Pyroglutamic acid salt of amlodipine
ATE270551T1 (en) COMBINATION PREPARATION OF 2-METHYLTHIAZOLIDINE-2,4-DICARBONIC ACID AND PARACETAMOL
PT1202956E (en) THERAPEUTIC AND / OR NURITIONALLY IMPROVED DERIVATIVES OF ACTIVE INGREDIENTS AND ORAL ADMINISTRATION COMPOSITIONS CONTAINING THE SAME
ME00088B (en) Paracetamol and drotaverine containing composition
ATE275577T1 (en) PHARMACEUTICALLY ACTIVE COMPOSITION CONTAINING QUINAPRIL MAGNESIUM